1731TiP Obrixtamig (BI 764532) in patients (pts) with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): Trial in progress of the dose expansion part of the phase II DAREON®-5 trial
作者
Marianne Pavel,Chris Verslype,P.F. Simoes da Rocha,A. Greystoke,Amrita Chauhan,J. Koevi,M. Müller,Ethan Y. Song,E. Bergsland